Compare FMX & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMX | IQV |
|---|---|---|
| Founded | 1890 | 1982 |
| Country | Mexico | United States |
| Employees | N/A | 93000 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4B | 43.1B |
| IPO Year | 1998 | 2013 |
| Metric | FMX | IQV |
|---|---|---|
| Price | $131.85 | $266.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 20 |
| Target Price | $135.93 | ★ $311.89 |
| AVG Volume (30 Days) | 793.7K | ★ 1.2M |
| Earning Date | 10-28-2026 | 10-27-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 5.24 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $7.78 | $7.18 |
| Revenue Next Year | $7.89 | $6.34 |
| P/E Ratio | ★ $40.94 | $51.73 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $92.55 | $154.50 |
| 52 Week High | $141.47 | $284.50 |
| Indicator | FMX | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 64.47 | 47.85 |
| Support Level | $121.26 | $252.49 |
| Resistance Level | $134.52 | $276.99 |
| Average True Range (ATR) | 2.95 | 10.13 |
| MACD | 0.31 | -0.30 |
| Stochastic Oscillator | 82.87 | 44.87 |
Mexico-based Femsa is a beverage and retail conglomerate in Central and South America. The holding company owns controlling stakes in bottler Coca-Cola Femsa (47% economic stake, 56% voting rights), in addition to operating 100%-owned retail assets, including convenience stores under the Oxxo banner, drugstores, and gas stations. The firm divested its 15% stake in Heineken and its distribution business in 2023. Coca-Cola Femsa and the Oxxo chain made up over 70% of total company revenue and over 90% of profits in 2025.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.